폐암 게놈 검사약 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 기술별, 검체 유형별, 패널 유형별, 최종사용자별, 지역별, 경쟁별 세분화(2020-2030년)

Lung Cancer Genomic Testing Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Sample Type, By Panel Type, By End-User, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,708,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 8,199,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,926,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 폐암 게놈 검사 의약품 시장은 2024년 19억 달러에서 2030년까지 25억 9,000만 달러로, CAGR 5.30%로 성장할 것으로 예측됩니다. 폐암 게놈 검사 의약품은 종양의 데옥시리보핵산(DNA)을 분석하여 특정 유전자 돌연변이 및 변화를 확인함으로써 환자 개개인에 맞는 치료 전략을 선택할 수 있도록 하는 의약품입니다. 시장 성장은 주로 전 세계 폐암 발생률 증가, 차세대 시퀀싱과 같은 유전체 시퀀싱 기술의 지속적인 발전, 종양학에서 정밀의료 접근법의 필요성이 증가함에 따라 주도되고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	19억 달러
시장 규모 : 2030년	25억 9,000만 달러
CAGR : 2025-2030년	5.30%
가장 빠르게 성장하는 부문	중합효소 연쇄 반응
최대 시장	북미

주요 시장 성장 촉진요인

세계 폐암 게놈 검사제 시장은 전 세계 폐암 발생률 증가로 인해 큰 영향을 받고 있습니다. 이러한 질병 부담 증가로 인해 환자의 정밀한 계층화를 촉진하고 표적 치료 개입을 유도할 수 있는 첨단 진단 툴에 대한 수요가 급증하고 있습니다.

주요 시장 과제

첨단 게놈 검사에 따른 막대한 비용이 세계 폐암 게놈 검사 의약품 시장의 성장에 큰 장벽이 되고 있습니다. 높은 검사 비용은 특히 예산 제약에 직면한 의료 시스템과 종합적인 상환 정책이 충분히 확립되지 않은 지역에서 환자의 접근성을 직접적으로 제한합니다.

주요 시장 동향

인공지능(AI)과 머신러닝은 폐암 유전체 분석을 크게 강화하여 복잡한 데이터 분석의 속도와 정확성을 향상시키고 있습니다. 이러한 기술을 통해 표적치료에 필수적인 실용적인 돌연변이를 정확하게 식별할 수 있습니다.

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 폐암 게놈 검사약 시장 전망

• 시장 규모·예측
  • 금액별
• 시장 점유율·예측
  • 기술별(중합효소 연쇄 반응, 차세대 시퀀싱, 형광 In-Situ 하이브리다이제이션, 기타)
  • 검체 유형별(조직 생검, 액체생검)
  • 패널 유형별(멀티 유전자 패널, 단일 유전자 패널)
  • 최종사용자별(조사기관, 병원·진료소, 진단 검사실, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 폐암 게놈 검사약 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 폐암 게놈 검사약 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 폐암 게놈 검사약 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 폐암 게놈 검사약 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 폐암 게놈 검사약 시장 전망

• 시장 규모·예측
• 시장 점유율·예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병·인수
• 제품 출시
• 최근 동향

제13장 세계의 폐암 게놈 검사약 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• QIAGEN NV
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• CENTOGENE N.V.
• BGI Genomics Co. Ltd.
• CeGaT GmbH
• Illumina Inc.
• F. Hoffmann-La Roche Ltd

제16장 전략적 제안

제17장 조사회사 소개·면책사항

KSA

영문 목차

영문목차

The Global Lung Cancer Genomic Testing Medicine Market will grow from USD 1.90 Billion in 2024 to USD 2.59 Billion by 2030 at a 5.30% CAGR. Lung cancer genomic testing medicine encompasses the analysis of tumor deoxyribonucleic acid to identify specific genetic mutations or alterations, enabling the selection of personalized therapeutic strategies for patients. The market's growth is primarily driven by the rising global incidence of lung cancer, continuous advancements in genomic sequencing technologies such as Next-Generation Sequencing, and an increasing imperative for precision medicine approaches in oncology.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.90 Billion
Market Size 2030	USD 2.59 Billion
CAGR 2025-2030	5.30%
Fastest Growing Segment	Polymerase Chain Reaction
Largest Market	North America

Key Market Drivers

The market for global lung cancer genomic testing medicine is significantly influenced by the increasing worldwide incidence of lung cancer. This escalating disease burden creates an urgent demand for advanced diagnostic tools to facilitate precise patient stratification and guide targeted therapeutic interventions. Lung cancer consistently ranks as a leading cause of cancer-related mortality globally, necessitating innovation in diagnostic capabilities.

Key Market Challenges

The substantial cost associated with advanced genomic testing represents a significant impediment to the growth of the Global Lung Cancer Genomic Testing Medicine Market. High test expenses directly limit patient access, particularly in healthcare systems facing budgetary constraints or where comprehensive reimbursement policies are not fully established. This financial barrier can deter clinicians from ordering these essential tests and prevent patients from undergoing molecular profiling, thereby restricting the overall adoption rate of precision medicine strategies in lung cancer.

Key Market Trends

Artificial intelligence and machine learning are significantly enhancing lung cancer genomic interpretation, improving speed and accuracy for complex data analysis. These technologies enable precise identification of actionable mutations crucial for targeted therapies. For instance, the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer showcased an AI tool, DeepGEM, for gene mutation prediction from histopathology slides, with data from 3,658 patients analyzed.

Key Market Players

• QIAGEN NV
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• CENTOGENE N.V.
• BGI Genomics Co. Ltd.
• CeGaT GmbH
• Illumina Inc.
• F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Lung Cancer Genomic Testing Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Genomic Testing Medicine Market, By Technology:

• Polymerase Chain Reaction
• Next-Generation Sequencing
• Fluorescence In-Situ Hybridization
• Others

Lung Cancer Genomic Testing Medicine Market, By Sample Type:

• Tissue Biopsy
• Liquid Biopsy

Lung Cancer Genomic Testing Medicine Market, By Panel Type:

• Multi-Gene Panel
• Single-Gene Panel

Lung Cancer Genomic Testing Medicine Market, By End-User:

• Research Organization
• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Lung Cancer Genomic Testing Medicine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lung Cancer Genomic Testing Medicine Market.

Available Customizations:

Global Lung Cancer Genomic Testing Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Cancer Genomic Testing Medicine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, Others)
  • 5.2.2. By Sample Type (Tissue Biopsy, Liquid Biopsy)
  • 5.2.3. By Panel Type (Multi-Gene Panel, Single-Gene Panel)
  • 5.2.4. By End-User (Research Organization, Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Lung Cancer Genomic Testing Medicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Sample Type
  • 6.2.3. By Panel Type
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Sample Type
      • 6.3.1.2.3. By Panel Type
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Sample Type
      • 6.3.2.2.3. By Panel Type
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Sample Type
      • 6.3.3.2.3. By Panel Type
      • 6.3.3.2.4. By End-User

7. Europe Lung Cancer Genomic Testing Medicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Sample Type
  • 7.2.3. By Panel Type
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Sample Type
      • 7.3.1.2.3. By Panel Type
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Sample Type
      • 7.3.2.2.3. By Panel Type
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Sample Type
      • 7.3.3.2.3. By Panel Type
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Sample Type
      • 7.3.4.2.3. By Panel Type
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Sample Type
      • 7.3.5.2.3. By Panel Type
      • 7.3.5.2.4. By End-User

8. Asia Pacific Lung Cancer Genomic Testing Medicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Sample Type
  • 8.2.3. By Panel Type
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Sample Type
      • 8.3.1.2.3. By Panel Type
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Sample Type
      • 8.3.2.2.3. By Panel Type
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Sample Type
      • 8.3.3.2.3. By Panel Type
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Sample Type
      • 8.3.4.2.3. By Panel Type
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Sample Type
      • 8.3.5.2.3. By Panel Type
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Lung Cancer Genomic Testing Medicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Sample Type
  • 9.2.3. By Panel Type
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lung Cancer Genomic Testing Medicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Sample Type
      • 9.3.1.2.3. By Panel Type
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Lung Cancer Genomic Testing Medicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Sample Type
      • 9.3.2.2.3. By Panel Type
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Lung Cancer Genomic Testing Medicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Sample Type
      • 9.3.3.2.3. By Panel Type
      • 9.3.3.2.4. By End-User

10. South America Lung Cancer Genomic Testing Medicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Sample Type
  • 10.2.3. By Panel Type
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lung Cancer Genomic Testing Medicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Sample Type
      • 10.3.1.2.3. By Panel Type
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Lung Cancer Genomic Testing Medicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Sample Type
      • 10.3.2.2.3. By Panel Type
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Lung Cancer Genomic Testing Medicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Sample Type
      • 10.3.3.2.3. By Panel Type
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lung Cancer Genomic Testing Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. QIAGEN NV
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Agilent Technologies Inc.
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. Quest Diagnostics Incorporated
• 15.5. Laboratory Corporation of America Holdings
• 15.6. CENTOGENE N.V.
• 15.7. BGI Genomics Co. Ltd.
• 15.8. CeGaT GmbH
• 15.9. Illumina Inc.
• 15.10. F. Hoffmann-La Roche Ltd

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료